Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 3/20 | 0.50 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 10/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | GRPR | P30550 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247979 | 0.96 | CCKBR (0.53) | PRMT1MAGI3CCKBRIL23RRXFP1 | |
| SCHEMBL30342394 | 0.94 | MAGI3 (0.54) | PRMT1MAGI3CCKBRCCKARIL23R | |
| SCHEMBL29939669 | 0.90 | PRMT1 (0.58) | PRMT1MAGI3CCKBRCCKARIL23R | |
| SCHEMBL31018602 | 0.89 | MAGI3 (0.56) | PRMT1MAGI3CCKBRIL23RRXFP1 | |
| SCHEMBL30903449 | 0.86 | OPRD1 (0.53) | PRMT1MAGI3CCKBRCCKAR | |
| SCHEMBL31442335 | 0.84 | MAGI3 (0.56) | PRMT1MAGI3CCKBRCCKARIL23R | |
| SCHEMBL30692610 | 0.82 | IL23R (0.59) | CCKBRCCKARIL23RGRPR | |
| SCHEMBL30810352 | 0.82 | PRMT1 (0.57) | PRMT1CCKBRCCKARGRPR | |
| SCHEMBL30051843 | 0.82 | ACE (0.56) | — | |
| SCHEMBL30051924 | 0.82 | ACE (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| EP-4392440-A2 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | River 2 Renal Corp. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2023-08-15 | — | — | US | disclosed |
| WO-2023028008-A2 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | RIVER 2 RENAL CORP. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | RXFP1, RXFP2, RXFP4 | PRMT1 562/4885MAGI3 2402/4885CCKBR 104/4885 |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SCTR, RXFP1, RXFP3 | PRMT1 2161/4885MAGI3 3680/4885CCKBR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.